FIELD: medicine.
SUBSTANCE: invention refers to medicine and immunology and concerns a conjugate for immunisation and vaccination and method for improving immunogenicity. Substance of the invention involves said conjugate for immunisation and vaccination representing an immunogen covalently bonded with a high-molecular carrier that is acidic peptidoglycane of molecular weight 1200-40000 KDa, and having the mass ratio of glucose and uronic acids 1:2-4.
EFFECT: advantage of the invention consists in improved immunogenicity 10-100 times higher, that in turn allows reducing immunogen doses in 10-100 times to achieve the same effect.
6 cl, 6 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREPARING SUBSTANCE SHOWING IMMUNOSTIMULATING, ANTIVIRAL AND ANTIBACTERIAL ACTIVITY, SUBSTANCE OBTAINED BY THIS METHOD AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2195308C1 |
| BROAD-SPECTRUM M2 PROTEIN ECTODOMAIN AVIAN INFLUENZA TYPE A VACCINE | 2014 |
|
RU2571944C1 |
| RECOMBINANT TRIVALENT INFLUENZA VACCINE | 2012 |
|
RU2485973C1 |
| VACCINE FOR HELMINTHIASIS CONTROL | 1996 |
|
RU2095082C1 |
| PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
| VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743595C1 |
| PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
| POLYSACCHARIDE-PROTEIN CONJUGATE POLYSACCHARIDE-PROTEIN FOR INDUCING IMMUNE RESPONSE AND PROTECTION AGAINST Staphylococcus aureus INFECTION, METHODS OF CONJUGATE OBTAINING (VERSIONS), CONJUGATE-CONTAINING COMPOSITION AND METHODS OF INDUCING IMMUNE RESPONSE AND PREVENTION OF Staphylococcus aureus INFECTION | 2010 |
|
RU2531234C2 |
| PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
| PHARMACEUTICAL COMPOSITION OF PATTERN-RECOGNISING RECEPTOR LIGANDS, METHODS FOR USING IT AS IMMUNOSTIMULANT FOR TREATING INFECTION CAUSED BY BACTERIAL AND VIRAL PATHOGENS, METHOD FOR USING IT AS ADJUVANT OF VACCINES | 2012 |
|
RU2497541C1 |
